The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
Open accessAbstract
The oncometabolite 2-hydroxyglutarate renders IDH1/2 mutant cancer cells deficient in homologous recombination and confers vulnerability to synthetic lethal targeting with PARP inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Self-citationRecurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature · doi:10.1038/nature10866 · Cited by 1,974
The comet assay: a method to measure DNA damage in individual cells
Olive, P. L., & Banáth, J. P. (2006) · Nature Protocols · doi:10.1038/nprot.2006.5 · Cited by 1,835
XRCC3 promotes homology-directed repair of DNA damage in mammalian cells
Pierce, A. J., Johnson, R. D., Thompson, L. H., & Jasin, M. (1999) · Genes & Development · doi:10.1101/gad.13.20.2633 · Cited by 1,379
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
Krauthammer, M., Kong, Y., Ha, B. H., Evans, P., Bacchiocchi, A., McCusker, J. P., Cheng, E., Davis, M. J., Goh, G., Choi, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.2359 · Cited by 1,191
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153
Amary, M. F., Bacsi, K., Maggiani, F., Damato, S., Halai, D., Berisha, F., Pollock, R., O'Donnell, P., Grigoriadis, A., Diss, T., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2913 · Cited by 1,023
Donawho, C. K., Luo, Y., Luo, Y., Penning, T. D., Bauch, J. L., Bouska, J. J., Bontcheva-Diaz, V. D., Cox, B. F., DeWeese, T. L., Dillehay, L. E., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3039 · Cited by 773
Combenefit: an interactive platform for the analysis and visualization of drug combinations
Di Veroli, G. Y., Fornari, C., Wang, D., Mollard, S., Bramhall, J. L., Richards, F. M., & Jodrell, D. I. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw230 · Cited by 736
OpenComet: An automated tool for comet assay image analysis
Gyori, B. M., Venkatachalam, G., Thiagarajan, P. S., Hsu, D., & Clement, M.-V. (2014) · Redox Biology · doi:10.1016/j.redox.2013.12.020 · Cited by 717
Jiao, Y., Pawlik, T. M., Anders, R. A., Selaru, F. M., Streppel, M. M., Lucas, D. J., Niknafs, N., Guthrie, V. B., Maitra, A., Argani, P., et al. (2013) · Nature Genetics · doi:10.1038/ng.2813 · Cited by 684
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2010) · Nature · doi:10.1038/nature09132 · Cited by 613
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
Chan, S. M., Thomas, D., Corces-Zimmerman, M. R., Xavy, S., Rastogi, S., Hong, W.-J., Zhao, F., Medeiros, B. C., Tyvoll, D. A., & Majeti, R. (2015) · Nature Medicine · doi:10.1038/nm.3788 · Cited by 577
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
Losman, J.-A., & Kaelin, W. G. (2013) · Genes & Development · doi:10.1101/gad.217406.113 · Cited by 570
Tracing compartmentalized NADPH metabolism in the cytosol and mitochondria of mammalian cells
Lewis, C. A., Parker, S. J., Fiske, B. P., McCloskey, D., Gui, D. Y., Green, C. R., Vokes, N. I., Feist, A. M., Vander Heiden, M. G., & Metallo, C. M. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.008 · Cited by 562
Oza, A. M., Cibula, D., Benzaquen, A. O., Poole, C., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71135-0 · Cited by 547
Patel, A. G., Sarkaria, J. N., & Kaufmann, S. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013715108 · Cited by 541
Hypoxia Induces Production of L-2-Hydroxyglutarate
Intlekofer, A. M., Dematteo, R. G., Venneti, S., Finley, L. W. S., Lu, C., Judkins, A. R., Rustenburg, A. S., Grinaway, P. B., Chodera, J. D., Cross, J. R., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.06.023 · Cited by 513
IDH mutations in cancer and progress toward development of targeted therapeutics
Dang, L., Yen, K., & Attar, E. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw013 · Cited by 509
Targeting cancer with kinase inhibitors
Gross, S., Rahal, R., Stransky, N., Lengauer, C., & Hoeflich, K. P. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76094 · Cited by 444
NAD + Depletion Is Necessary and Sufficient forPoly(ADP-Ribose) Polymerase-1-Mediated Neuronal Death
Alano, C. C., Garnier, P., Ying, W., Higashi, Y., Kauppinen, T. M., & Swanson, R. A. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5552-09.2010 · Cited by 439 · cited 1×
“a substrate (45), we examined nitric acid dihydrate (NAD) status under the conditions of our experiments.”
BackgroundExtreme vulnerability of IDH1 mutant cancers to NAD+ depletion
Tateishi, K., Wakimoto, H., Iafrate, A. J., Tanaka, S., Loebel, F., Lelic, N., Wiederschain, D., Bedel, O., Deng, G., Zhang, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.006 · Cited by 433
MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis
Terunuma, A., Putluri, N., Mishra, P., Mathé, E. A., Dorsey, T. H., Yi, M., Wallace, T. A., Issaq, H. J., Zhou, M., Killian, J. K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71180 · Cited by 428
Cairncross, J. G., Wang, M., Jenkins, R. B., Shaw, E. G., Giannini, C., Brachman, D. G., Buckner, J. C., Fink, K. L., Souhami, L., Laperriere, N. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3726 · Cited by 402
Wang, P., Dong, Q., Zhang, C., Kuan, P.-F., Liu, Y., Jeck, W. R., Andersen, J. B., Jiang, W., Savich, G. L., Tan, T.-X., et al. (2013) · Oncogene · doi:10.1038/onc.2012.315 · Cited by 399
Self-citationHuman Fanconi anemia monoubiquitination pathway promotes homologous DNA repair
Nakanishi, K., Yang, Y.-G., Pierce, A. J., Taniguchi, T., Digweed, M., D'Andrea, A. D., Wang, Z.-Q., & Jasin, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407796102 · Cited by 384
Oldham, W. M., Clish, C. B., Yang, Y., & Loscalzo, J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.06.021 · Cited by 364 · cited 3×
“Knockdown of L2HGDH, which metabolizes (S)-2HG, was recently shown to increase (S)-2HG in log-phase, normoxic cells (12).”
BackgroundMallette, F. A., Mattiroli, F., Cui, G., Young, L. C., Hendzel, M. J., Mer, G., Sixma, T. K., & Richard, S. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.47 · Cited by 355
Integrated genomic characterization of IDH1-mutant glioma malignant progression
Bai, H., Harmancı, A. S., Erson-Omay, E. Z., Li, J., Coşkun, S., Simon, M., Krischek, B., Özduman, K., Omay, S. B., Sorensen, E. A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3457 · Cited by 329
Self-citationSakai, W., Swisher, E. M., Jacquemont, C., Chandramohan, K. V., Couch, F. J., Langdon, S. P., Wurz, K., Higgins, J., Villegas, E., & Taniguchi, T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1178 · Cited by 321
Bleeker, F. E., Atai, N. A., Lamba, S., Jonker, A., Rijkeboer, D., Bosch, K. S., Tigchelaar, W., Troost, D., Vandertop, W. P., Bardelli, A., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0645-6 · Cited by 302
l -2-Hydroxyglutarate: An Epigenetic Modifier and Putative Oncometabolite in Renal Cancer
Shim, E.-H., Livi, C. B., Rakheja, D., Tan, J., Benson, D., Parekh, V., Kho, E.-Y., Ghosh, A. P., Kirkman, R., Velu, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0696 · Cited by 280
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
de Botton, S., Mondesir, J., Willekens, C., & Touat, M. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s70716 · Cited by 220
Molenaar, R. J., Verbaan, D., Lamba, S., Zanon, C., Jeuken, J. W. M., Boots-Sprenger, S. H. E., Wesseling, P., Hulsebos, T. J. M., Troost, D., van Tilborg, A. A., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou005 · Cited by 207
Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer
Clark, O., Yen, K., & Mellinghoff, I. K. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1333 · Cited by 206
Lee, J.-M., Hays, J. L., Annunziata, C. M., Noonan, A. M., Minasian, L., Zujewski, J. A., Yu, M., Gordon, N., Ji, J., Sissung, T. M., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju089 · Cited by 184
Molecular and Biochemical Characterization of xrs Mutants Defective in Ku80
Singleton, B. K., Priestley, A., Steingrimsdottir, H., Gell, D., Blunt, T., Jackson, S. P., Lehmann, A. R., & Jeggo, P. A. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.3.1264 · Cited by 180
Young, L. C., McDonald, D., & Hendzel, M. J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.491514 · Cited by 151
Hypoxia-Induced Epigenetic Regulation and Silencing of the BRCA1 Promoter
Lü, Y., Chu, A., Turker, M. S., & Glazer, P. M. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01121-10 · Cited by 141
Self-citationZhuang, J., Zhang, J., Willers, H., Wang, H., Chung, J. H., van Gent, D. C., Hallahan, D. E., Powell, S. N., & Xia, F. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3278 · Cited by 132
Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations
Emir, U. E., Larkin, S. J., de Pennington, N., Voets, N., Plaha, P., Stacey, R. J., Al-Qahtani, K., McCullagh, J., Schofield, C. J., Clare, S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0934 · Cited by 125
Ruis, B. L., Fattah, K. R., & Hendrickson, E. A. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00355-08 · Cited by 122
Li, L., Paz, A. C., Wilky, B. A., Johnson, B. A., Galoian, K. A., Rosenberg, A. E., Hu, G., Tinoco, G., Bodamer, O. A., & Trent, J. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133813 · Cited by 115
Tran, A. N., Lai, A., Li, S., Pope, W. B., Teixeira, S., Harris, R. J., Woodworth, D. C., Nghiemphu, P. L., Cloughesy, T. F., & Ellingson, B. M. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not198 · Cited by 113
Chu, C., Wang, L., Hsu, K., Chen, C.-C., Cheng, H.-H., Wang, S.-M., Wu, C.-M., Chen, T., Li, L.-T., Liu, R., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500249n · Cited by 106
The Contribution of Ketone Bodies to Basal and Activity-Dependent Neuronal Oxidation in Vivo
Chowdhury, G. M. I., Jiang, L., Rothman, D. L., & Behar, K. L. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.77 · Cited by 103
Bindra, R. S., Goglia, A. G., Jasin, M., & Powell, S. N. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt255 · Cited by 103
Self-citationWang, L., Hung, C.-L., Chen, Y.-R., Yang, J. C., Wang, J., Campbell, M., Izumiya, Y., Chen, H.-W., Wang, W., Ann, D. K., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.018 · Cited by 101
Drugging ATR: Progress in the Development of Specific Inhibitors for the Treatment of Cancer
Foote, K. M., Lau, A., & Nissink, J. W. M. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.33 · Cited by 92
Baader, E., Tschank, G., Baringhaus, K. H., Burghard, H., & Günzler, V. (1994) · Biochemical Journal · doi:10.1042/bj3000525 · Cited by 91
Survival of the Replication Checkpoint Deficient Cells Requires MUS81-RAD52 Function
Murfuni, I., Basile, G., Subramanyam, S. V., Malacaria, E., Bignami, M., Spies, M., Franchitto, A., & Pichierri, P. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003910 · Cited by 83
Jackson, S. P., & Helleday, T. (2016) · Science · doi:10.1126/science.aab0958 · Cited by 83
Su, J. M. F., Thompson, P., Adesina, A. M., Li, X., Kilburn, L. B., Onar‐Thomas, A., Koçak, M., Chyla, B., McKeegan, E. M., Warren, K. E., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou103 · Cited by 75
Distinct binding of BRCA2 BRC repeats to RAD51 generates differential DNA damage sensitivity
Chatterjee, G., Jiménez-Sáinz, J., Presti, T., Nguyen, T. T. M., & Jensen, R. B. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw242 · Cited by 71
Ju, H., Zhuang, Z.-N., Li, H., Tian, T., Lu, Y., Fan, X.-Q., Zhou, H. S., Mo, H., Sheng, H., Chiao, P. J., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.05.024 · Cited by 71
Enzymatic assay for quantitative analysis of (d)-2-hydroxyglutarate
Balß, J., Pusch, S., Beck, A.-C., Herold‐Mende, C. C., Krämer, A., Thiede, C., Buckel, W., Langhans, C., Okun, J. G., & von Deimling, A. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1060-y · Cited by 71
Kortmann, U., McAlpine, J. N., Xue, H., Guan, J., Ha, G., Tully, S., Shafait, S., Lau, A., Cranston, A. N., O’Connor, M. J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1382 · Cited by 70
Surovtseva, Y. V., Jairam, V., Salem, A. F., Sundaram, R. K., Bindra, R. S., & Herzon, S. B. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b00162 · Cited by 66
Self-citationCzochor, J. R., Sulkowski, P. L., & Glazer, P. M. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0399 · Cited by 56
Self-citationSynthetic Lethal Vulnerabilities of Cancer
de la Cruz, F. F., Gapp, B. V., & Nijman, S. M. B. (2014) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124511 · Cited by 51
Hypoxic Stress Facilitates Acute Activation and Chronic Downregulation of Fanconi Anemia Proteins
Scanlon, S. E., & Glazer, P. M. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0628 · Cited by 48
Self-citationBasal repression of BRCA1 by multiple E2Fs and pocket proteins at adjacent E2F sites
Bindra, R. S., & Glazer, P. M. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.10.3454 · Cited by 42
Self-citationGoglia, A. G., Delsite, R., Luz, A. N., Shahbazian, D., Salem, A. F., Sundaram, R. K., Chiaravalli, J., Hendrikx, P. J., Wilshire, J. A., Jasin, M., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0765 · Cited by 42
Self-citationReductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells
Smolková, K., Dvořák, A., Zelenka, J., Vítek, L., & Ježek, P. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.05.012 · Cited by 40
Muscal, J. A., Thompson, P. A., Giranda, V. L., Dayton, B. D., Bauch, J. L., Horton, T. M., McGuffey, L., Nuchtern, J. G., Dauser, R. C., Gibson, B. W., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1044-3 · Cited by 35
Stachelek, G. C., Peterson-Roth, E., Liu, Y., Fernandez, R. J., Pike, L., Qian, J. M., Abriola, L., Hoyer, D., Hungerford, W. M., Merkel, J., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0036 · Cited by 19
Self-citationBabakoohi, S., Lapidus, R. G., Faramand, R. G., Sausville, E. A., & Emadi, A. (2016) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000342 · Cited by 9
Cited by
Cancer metabolism: looking forward
Martínez-Reyes, I., & Chandel, N. S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00378-6 · Cited by 1,824
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
Knijnenburg, T. A., Wang, L., Zimmermann, M. T., Chambwe, N., Gao, G. F., Cherniack, A. D., Fan, H., Shen, H., Way, G. P., Greene, C. S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.076 · Cited by 1,136
Self-citationMetabolic reprogramming and epigenetic modifications on the path to cancer
Sun, L., Zhang, H., & Gao, P. (2022) · Protein & Cell · doi:10.1007/s13238-021-00846-7 · Cited by 770
IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
Han, S., Liu, Y., Cai, S. J., Qian, M., Ding, J., Larion, M., Gilbert, M. R., & Yang, C. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0814-x · Cited by 657
Self-citation
Metadata
- Authors
- Sulkowski, P. L., Corso, C. D., Robinson, N. D., Scanlon, S. E., Purshouse, K. R., Bai, H., Liu, Y., Sundaram, R. K., Hegan, D. C., Fons, N. R., Breuer, G. A., Song, Y., Mishra-Gorur, K., De Feyter, H. M., de Graaf, R. A., Surovtseva, Y. V., Kachman, M., Halene, S., Günel, M., Glazer, P. M., & Bindra, R. S.
- Venue
- Science Translational Medicine
- Published
- 2017-02
- Volume
- 9
- Issue
- 375
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2585230893
- Cited by
- 555
- References
- 71
- FWCI
- 22.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.